- Home
- BANX vs GALT Comparison
BANX vs GALT Comparison
Compare BANX & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANX | GALT |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.0M | 203.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BANX | GALT |
|---|---|---|
| Price | $21.00 | $2.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 23.4K | ★ 386.8K |
| Earning Date | 06-17-2025 | 11-14-2025 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $29,467,794.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.88 | ★ N/A |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $17.99 | $1.12 |
| 52 Week High | $21.67 | $7.13 |
Technical Indicators
Market Signals| Indicator | BANX | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 38.97 |
| Support Level | $20.80 | $2.76 |
| Resistance Level | $21.56 | $3.30 |
| Average True Range (ATR) | 0.48 | 0.24 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 32.64 | 25.62 |
Price Performance
Historical ComparisonAbout BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.